A major pooled analysis published in JAMA has shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors deliver consistent ...

In a retrospective study, repetitive transcranial magnetic stimulation produces weight loss comparable to semaglutide 0.5 ...

A recent study found that Sodium-glucose co-transporter 2 (SGLT2) inhibitors use in hypertrophic cardiomyopathy (HCM) ...

ENYO Pharma ("ENYO"), a clinical-stage biopharmaceutical company developing innovative therapies for kidney diseases, today ...

Please provide your email address to receive an email when new articles are posted on . Treatment with SGLT2 inhibitors was associated with decreased mortality but increased incidence of lupus ...

A recent review examined how widely used treatments such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists may ...

SaveHealth reports on managing type 2 diabetes through medications, lifestyle changes, and support, highlighting various ...

And in a phase III trial win, Foresee Pharmaceuticals said its long-acting gonadotropin-releasing hormone agonist leuprolide ...

At the 2025 AMCP annual meeting in Houston, John M. O'Brien, Pharm.D., M.P.H., president and CEO of the National ...

Common diabetes drugs may do more than regulate blood sugar—they could also influence how cancers grow, spread, or slow down.

A normal echocardiogram doesn't always mean a healthy heart. Persistent symptoms like breathlessness and fatigue can indicate ...

With rates of juvenile type 2 diabetes rocketing in the US, doctors now have access to an alternative oral therapy – the first new oral option for more than 20 years. Eli Lilly and Boehringer ...